Inovio Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INO)

$4.40 0.12 (2.80 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$4.40
Today's Range$4.21 - $4.41
52-Week Range$4.20 - $9.86
Volume1.41 million shs
Average Volume1.27 million shs
Market Capitalization$397.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.75

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:INO
CUSIPN/A
Phone+1-858-5976006

Debt

Debt-to-Equity RatioN/A
Current Ratio4.63%
Quick Ratio4.63%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.37 million
Price / Sales11.23
Cash FlowN/A
Price / CashN/A
Book Value$1.67 per share
Price / Book2.63

Profitability

Trailing EPS($1.18)
Net Income$-73,740,000.00
Net Margins-221.55%
Return on Equity-72.19%
Return on Assets-53.91%

Miscellaneous

Employees253
Outstanding Shares90,300,000

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?

Inovio Pharmaceuticals declared a monthly dividend on Thursday, September 21st. Investors of record on Friday, September 29th will be given a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 18.82%. The ex-dividend date is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.15. The biopharmaceutical company had revenue of $2.60 million for the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. Inovio Pharmaceuticals's quarterly revenue was down 79.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.28) EPS. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?

10 brokerages have issued 1 year price objectives for Inovio Pharmaceuticals' stock. Their predictions range from $10.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $20.20 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.

What are Wall Street analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio reported wider-than-expected loss in the third quarter of 2017 with revenue missing estimates. As the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Meanwhile highly lucrative immuno-oncology market has been the focus area of several big pharma giants which may pose intense competition to the candidates once approved. Shares of the company have underperformed the industry so far this year. However, we are positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging." (11/13/2017)
  • 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:

  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Peter D. Kies, Chief Financial Officer (Age 53)
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer (Age 49)
  • Mark L. Bagarazzi M.D., Chief Medical Officer (Age 56)
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board (Age 56)
  • George W. Bickerstaff III, Director (Age 61)
  • David B. Weiner, Director (Age 61)
  • Wendy L. Yarno, Director (Age 63)
  • Simon X. Benito, Independent Director (Age 72)

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (2.98%), Bank of New York Mellon Corp (0.42%), Allianz Asset Management GmbH (0.25%), Alyeska Investment Group L.P. (0.16%), Swiss National Bank (153,718.28%) and New York State Common Retirement Fund (0.14%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Russell Investments Group Ltd., GSA Capital Partners LLP and Stoneridge Investment Partners LLC. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner and Jong Joseph Kim. View Insider Buying and Selling for Inovio Pharmaceuticals.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., OxFORD Asset Management LLP, Wasatch Advisors Inc., Bank of New York Mellon Corp, ING Groep NV, Swiss National Bank, Allianz Asset Management GmbH and Belpointe Asset Management LLC. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $4.40.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $397.30 million and generates $35.37 million in revenue each year. The biopharmaceutical company earns $-73,740,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Inovio Pharmaceuticals employs 253 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 10480 Wateridge Cir, SAN DIEGO, CA 92121-5773, United States. The biopharmaceutical company can be reached via phone at +1-858-5976006 or via email at [email protected]


MarketBeat Community Rating for Inovio Pharmaceuticals (INO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Inovio Pharmaceuticals (NASDAQ:INO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.752.73
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.75$19.75$20.55$21.60
Price Target Upside: 336.95% upside326.57% upside240.72% upside166.67% upside

Inovio Pharmaceuticals (NASDAQ:INO) Consensus Price Target History

Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2017HC WainwrightSet Price TargetBuy$13.00MediumView Rating Details
10/18/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$11.00N/AView Rating Details
10/6/2017CitigroupInitiated CoverageBuy$10.00N/AView Rating Details
9/12/2017Maxim GroupReiterated RatingBuy$12.00LowView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies GroupReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
5/25/2016National Bank FinancialDowngradeOutperform Market Weight -> Sector Perform Market WeightN/AView Rating Details
3/28/2016DesjardinsDowngradeBuy -> HoldN/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Inovio Pharmaceuticals (NASDAQ:INO) Earnings History and Estimates Chart

Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ INO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 17($0.25)($0.40)$10.27 million$2.60 millionViewN/AView Earnings Details
8/8/2017Q2 17($0.21)($0.13)$16.29 million$20.41 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/15/2014$0.22$0.22$4.63 million$4.66 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
5/7/2014$0.20$0.23$4.63 million$4.89 millionViewN/AView Earnings Details
3/22/2014$0.20$0.24ViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Inovio Pharmaceuticals (NASDAQ:INO) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.12 EPS
Next Year EPS Consensus Estimate: $-1.28 EPS

Dividends

Inovio Pharmaceuticals (NASDAQ:INO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/21/2017Monthly$0.079/28/20179/29/201710/16/2017
8/22/2017Monthly$0.078/29/20178/31/20179/15/2017
7/25/2017Monthly$0.077/27/20177/31/20178/15/2017
6/23/2017Monthly$0.076/28/20176/30/20177/17/2017
(Data available from 1/1/2013 forward)

Insider Trades

Inovio Pharmaceuticals (NASDAQ INO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 32.27%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ INO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.20View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.00View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Inovio Pharmaceuticals (NASDAQ INO) News Headlines

Source:
DateHeadline
Heres Why Inovio Pharmaceuticals Inc. Fell 21.3% in November - Motley FoolHere's Why Inovio Pharmaceuticals Inc. Fell 21.3% in November - Motley Fool
www.fool.com - December 12 at 3:24 PM
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development - GlobeNewswire (press release)Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development - GlobeNewswire (press release)
globenewswire.com - December 11 at 9:42 AM
Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound? - NasdaqInovio (INO) Down 15.5% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - December 11 at 9:42 AM
Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?
finance.yahoo.com - December 11 at 9:42 AM
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & DevelopmentInovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
finance.yahoo.com - December 11 at 9:42 AM
Zacks: Brokerages Expect Inovio Pharmaceuticals, Inc. (INO) Will Announce Quarterly Sales of $7.75 MillionZacks: Brokerages Expect Inovio Pharmaceuticals, Inc. (INO) Will Announce Quarterly Sales of $7.75 Million
www.americanbankingnews.com - December 10 at 7:54 AM
Inovio Pharmaceuticals, Inc. (INO) Receives Average Rating of "Hold" from BrokeragesInovio Pharmaceuticals, Inc. (INO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 7 at 2:04 AM
Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors - GlobeNewswire (press release)Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors - GlobeNewswire (press release)
globenewswire.com - December 6 at 3:23 PM
Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of DirectorsInovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors
finance.yahoo.com - December 6 at 8:13 AM
ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 5, 2017ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:24 PM
Detailed Research: Economic Perspectives on CVS Health, FirstEnergy, Welbilt, Inc., Rockwell Collins, Sprouts Farmers Market, and Inovio Pharmaceuticals — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on CVS Health, FirstEnergy, Welbilt, Inc., Rockwell Collins, Sprouts Farmers Market, and Inovio Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - December 1 at 8:39 AM
Inovio Pharma (INO) Says Further Analysis of VGX-3100 Phase 2b ... - StreetInsider.comInovio Pharma (INO) Says Further Analysis of VGX-3100 Phase 2b ... - StreetInsider.com
www.streetinsider.com - November 30 at 7:54 AM
BRIEF-Inovio Announces Analysis Of VGX-3100 Phase 2b DataBRIEF-Inovio Announces Analysis Of VGX-3100 Phase 2b Data
www.reuters.com - November 29 at 9:01 AM
Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical EfficacyInovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
finance.yahoo.com - November 29 at 9:01 AM
Inovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright AnalystsInovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - November 28 at 9:50 AM
Inovio Pharma (INO): Checkpoint Combo Results In Significant Preclinical Improvement - HC Wainwright - StreetInsider.comInovio Pharma (INO): Checkpoint Combo Results In Significant Preclinical Improvement - HC Wainwright - StreetInsider.com
www.streetinsider.com - November 28 at 9:35 AM
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically ... - GlobeNewswire (press release)Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically ... - GlobeNewswire (press release)
globenewswire.com - November 27 at 5:22 PM
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor ModelInovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
finance.yahoo.com - November 27 at 5:22 PM
Inovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $7.75 MillionInovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $7.75 Million
www.americanbankingnews.com - November 22 at 4:28 AM
 Analysts Anticipate Inovio Pharmaceuticals, Inc. (INO) to Post -$0.29 Earnings Per Share Analysts Anticipate Inovio Pharmaceuticals, Inc. (INO) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - November 20 at 3:18 PM
Inovio Pharmaceuticals, Inc. (INO) Expected to Announce Quarterly Sales of $7.75 MillionInovio Pharmaceuticals, Inc. (INO) Expected to Announce Quarterly Sales of $7.75 Million
www.americanbankingnews.com - November 15 at 8:28 AM
Zacks Investment Research Downgrades Inovio Pharmaceuticals, Inc. (INO) to SellZacks Investment Research Downgrades Inovio Pharmaceuticals, Inc. (INO) to Sell
www.americanbankingnews.com - November 13 at 11:28 AM
Inovio Pharmaceuticals, Inc. (INO) Downgraded to "Sell" at Zacks Investment ResearchInovio Pharmaceuticals, Inc. (INO) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - November 13 at 11:28 AM
Inovio Pharma (INO) Presents Immuno-Oncology Advancements at SITCInovio Pharma (INO) Presents Immuno-Oncology Advancements at SITC
www.streetinsider.com - November 12 at 10:46 AM
Inovalis Real Estate Investment Trust (INO) Receives Consensus Rating of "Hold" from BrokeragesInovalis Real Estate Investment Trust (INO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 12 at 1:50 AM
Inovio Pharmaceuticals to Participate In Upcoming Investment ConferencesInovio Pharmaceuticals to Participate In Upcoming Investment Conferences
finance.yahoo.com - November 11 at 12:28 PM
What You Need to Know From Inovio Pharmaceuticals' Q3 UpdateWhat You Need to Know From Inovio Pharmaceuticals' Q3 Update
finance.yahoo.com - November 11 at 12:28 PM
Inovio (INO) Q3 Loss Wider Than Expected, Revenues MissInovio (INO) Q3 Loss Wider Than Expected, Revenues Miss
finance.yahoo.com - November 11 at 12:28 PM
Inovio Pharmaceuticals, Inc. (INO) Downgraded by ValuEngine to "Strong Sell"Inovio Pharmaceuticals, Inc. (INO) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - November 9 at 11:38 PM
EARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q3 Earnings Report
www.rttnews.com - November 9 at 6:49 AM
Inovio reports 3Q lossInovio reports 3Q loss
finance.yahoo.com - November 9 at 6:49 AM
Edited Transcript of INO earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of INO earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 6:49 AM
Inovio Pharmaceuticals, Inc. (INO) Releases Quarterly  Earnings Results, Misses Expectations By $0.15 EPSInovio Pharmaceuticals, Inc. (INO) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS
www.americanbankingnews.com - November 9 at 12:44 AM
Why Inovio Pharmaceuticals Stock Sank in October - Motley FoolWhy Inovio Pharmaceuticals Stock Sank in October - Motley Fool
www.fool.com - November 8 at 10:29 AM
Why Inovio Pharmaceuticals Stock Sank in October - Motley FoolWhy Inovio Pharmaceuticals Stock Sank in October - Motley Fool
www.fool.com - November 8 at 10:29 AM
Financial Survey: Ironwood Pharmaceuticals (IRWD) vs. Inovio Pharmaceuticals (INO)Financial Survey: Ironwood Pharmaceuticals (IRWD) vs. Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - November 6 at 3:26 AM
Inovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 MillionInovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 Million
www.americanbankingnews.com - November 2 at 10:52 AM
Inovio Pharmaceuticals (INO) & Oramed Pharmaceuticals (ORMP) Critical AnalysisInovio Pharmaceuticals (INO) & Oramed Pharmaceuticals (ORMP) Critical Analysis
www.americanbankingnews.com - November 2 at 3:08 AM
Inovio Pharma (INO) Initiates Study for Glioblastoma in Combination with Regenerons (REGN) PD-1 InhibitorInovio Pharma (INO) Initiates Study for Glioblastoma in Combination with Regeneron's (REGN) PD-1 Inhibitor
www.streetinsider.com - November 2 at 2:27 AM
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 InhibitorInovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
finance.yahoo.com - November 2 at 2:27 AM
Analyzing Inovio Pharmaceuticals (INO) and Fibrocell Science (FCSC)Analyzing Inovio Pharmaceuticals (INO) and Fibrocell Science (FCSC)
www.americanbankingnews.com - November 1 at 2:18 PM
Inovio Pharmaceuticals, Inc. (INO) Downgraded by BidaskClub to "Strong Sell"Inovio Pharmaceuticals, Inc. (INO) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - October 30 at 12:58 AM
Inovio Pharmaceuticals Is Now Oversold (INO)Inovio Pharmaceuticals Is Now Oversold (INO)
www.thestreet.com - October 26 at 6:56 PM
Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017 - NasdaqInovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017 - Nasdaq
www.nasdaq.com - October 26 at 1:52 PM
Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - October 26 at 1:52 PM
First Week Of INO December 15th Options TradingFirst Week Of INO December 15th Options Trading
www.thestreet.com - October 25 at 6:29 AM
Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical StudyInovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
finance.yahoo.com - October 25 at 6:29 AM
Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : October 24, 2017Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : October 24, 2017
finance.yahoo.com - October 25 at 6:28 AM
Montco vaccine developer posts positive results from Lassa fever virus studyMontco vaccine developer posts positive results from Lassa fever virus study
finance.yahoo.com - October 25 at 6:28 AM
Reviewing Inovio Pharmaceuticals (INO) & Its CompetitorsReviewing Inovio Pharmaceuticals (INO) & Its Competitors
www.americanbankingnews.com - October 24 at 12:30 PM

SEC Filings

Inovio Pharmaceuticals (NASDAQ:INO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Inovio Pharmaceuticals (NASDAQ:INO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Inovio Pharmaceuticals (NASDAQ INO) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.